Study identification

PURI

https://redirect.ema.europa.eu/resource/29058

EU PAS number

EUPAS21305

Study ID

29058

Official title and acronym

Claims Database Study of Utilization Patterns of Dimethyl Fumarate in Germany

DARWIN EU® study

No

Study countries

Germany

Study description

The primary objective of this study is to estimate the proportion of DMF use that is prescribed "on-label" versus "off-label". The secondary objectives are: To describe the demographic characteristics and medical history of DMF users, To describe prescription drug history and concomitant medication use of DMF users, To describe the duration of therapy in participants newly initiating DMF treatment, To describe the medical specialties of DMF prescribers.

Study status

Finalised
Research institutions and networks

Institutions

Biogen
First published:
01/02/2024
Institution

Contact details

Study Director Biogen

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Actual:

Data analysis start date

Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Biogen
Study protocol
Initial protocol
English (543.98 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)